Skip to main content
Top
Published in: Rheumatology International 11/2009

01-09-2009 | Original Paper

Clinical and serological correlates of anti-Sm autoantibodies in Chinese patients with systemic lupus erythematosus: 1,584 cases

Authors: Jin Dong Ni, Xi Yao, Hai Feng Pan, Xiang Pei Li, Jian Hua Xu, Dong Qing Ye

Published in: Rheumatology International | Issue 11/2009

Login to get access

Abstract

To investigate the association of anti-Sm antibodies with clinical and serological features in systemic lupus erythematosus. A group of 1,584 patients with SLE was recruited. Clinical and laboratory data were compared between patients with and without anti-Sm antibodies. There were 1,424 females and 160 males, the mean age of the patients was 33.2 ± 12.3 years, and the mean duration of disease was 32.5 ± 59.4 months. A total of 469 (29.6%) were anti-Sm antibodies positive. The presence of anti-Sm antibodies was associated with arthritis, renal involvement, malar rash, vasculitis and low serum complement C3. The positive rate of anti-nuclear, anti-dsDNA, anti-La/SSB and anti-U1RNP antibodies were significant higher in anti-Sm positive group when compared with anti-Sm negative group. A trend towards a higher presence of anti-Sm antibodies related to an early disease onset was observed. In conclusion, Anti-Sm antibodies are associated with lupus related clinical and laboratory profiles and correlated significantly with disease activity.
Literature
3.
go back to reference Yamasaki Y, Narain S, Yoshida H, Hernandez L, Barker T, Hahn PC et al (2007) Autoantibodies to RNA helicase A: a new serologic marker of early lupus. Arthritis Rheum 56:596–604. doi:10.1002/art.22329 PubMedCrossRef Yamasaki Y, Narain S, Yoshida H, Hernandez L, Barker T, Hahn PC et al (2007) Autoantibodies to RNA helicase A: a new serologic marker of early lupus. Arthritis Rheum 56:596–604. doi:10.​1002/​art.​22329 PubMedCrossRef
5.
go back to reference Malaviya AN, Singh RR, Kumar A, De A, Kumar A, Aradhye S (1988) Systemic lupus erythematosus in northern India: a review of 329 cases. J Assoc Physicians India 36:476–480PubMed Malaviya AN, Singh RR, Kumar A, De A, Kumar A, Aradhye S (1988) Systemic lupus erythematosus in northern India: a review of 329 cases. J Assoc Physicians India 36:476–480PubMed
6.
go back to reference Tikly M, Burgin S, Mohanlal P, Bellingan A, George J (1996) Autoantibodies in black South Africans with systemic lupus erythematosus: spectrum and clinical associations. Clin Rheumatol 15:261–265. doi:10.1007/BF02229704 PubMedCrossRef Tikly M, Burgin S, Mohanlal P, Bellingan A, George J (1996) Autoantibodies in black South Africans with systemic lupus erythematosus: spectrum and clinical associations. Clin Rheumatol 15:261–265. doi:10.​1007/​BF02229704 PubMedCrossRef
9.
go back to reference Alba P, Bento L, Cuadrado MJ, Karim Y, Tungekar MF, Abbs I et al (2003) Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis 62:556–560. doi:10.1136/ard.62.6.556 PubMedCrossRef Alba P, Bento L, Cuadrado MJ, Karim Y, Tungekar MF, Abbs I et al (2003) Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis 62:556–560. doi:10.​1136/​ard.​62.​6.​556 PubMedCrossRef
11.
go back to reference Gulko PS, Reveille JD, Koopman WJ, Burgard SL, Bartolucci AA, Alarcón GS (1994) Survival impact of autoantibodies in systemic lupus erythematosus. J Rheumatol 21:224–228PubMed Gulko PS, Reveille JD, Koopman WJ, Burgard SL, Bartolucci AA, Alarcón GS (1994) Survival impact of autoantibodies in systemic lupus erythematosus. J Rheumatol 21:224–228PubMed
12.
13.
go back to reference Janwityanujit S, Totemchokchyakarn K, Verasertniyom O, Vanichapuntu M, Vatanasuk M (1995) Age-related differences on clinical and immunological manifestations of SLE. Asian Pac J Allergy Immunol 13:145–149PubMed Janwityanujit S, Totemchokchyakarn K, Verasertniyom O, Vanichapuntu M, Vatanasuk M (1995) Age-related differences on clinical and immunological manifestations of SLE. Asian Pac J Allergy Immunol 13:145–149PubMed
14.
go back to reference Llorente MJ, Jiménez J, González C, Alarcón I, Alsina M, Casas LM et al (2005) Effectiveness of different methods for anti-Sm antibody identification. A multicentre study. Clin Chem Lab Med 43:748–752. doi:10.1515/CCLM.2005.128 PubMedCrossRef Llorente MJ, Jiménez J, González C, Alarcón I, Alsina M, Casas LM et al (2005) Effectiveness of different methods for anti-Sm antibody identification. A multicentre study. Clin Chem Lab Med 43:748–752. doi:10.​1515/​CCLM.​2005.​128 PubMedCrossRef
15.
go back to reference Girón-González JA, Moral FJ, Elvira J, García-Gil D, Guerrero F, Gavilán I et al (2000) Consistent production of a higher TH1:TH2 cytokine ratio by stimulated T cells in men compared with women. Eur J Endocrinol 143:31–36. doi:10.1530/eje.0.1430031 PubMedCrossRef Girón-González JA, Moral FJ, Elvira J, García-Gil D, Guerrero F, Gavilán I et al (2000) Consistent production of a higher TH1:TH2 cytokine ratio by stimulated T cells in men compared with women. Eur J Endocrinol 143:31–36. doi:10.​1530/​eje.​0.​1430031 PubMedCrossRef
16.
go back to reference Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA et al (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349:1526–1533. doi:10.1056/NEJMoa021933 PubMedCrossRef Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA et al (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349:1526–1533. doi:10.​1056/​NEJMoa021933 PubMedCrossRef
19.
go back to reference Ozbek S, Sert M, Paydas S, Soy M (2003) Delay in the diagnosis of SLE: the importance of arthritis/arthralgia as the initial symptom. Acta Med Okayama 57:187–190PubMed Ozbek S, Sert M, Paydas S, Soy M (2003) Delay in the diagnosis of SLE: the importance of arthritis/arthralgia as the initial symptom. Acta Med Okayama 57:187–190PubMed
Metadata
Title
Clinical and serological correlates of anti-Sm autoantibodies in Chinese patients with systemic lupus erythematosus: 1,584 cases
Authors
Jin Dong Ni
Xi Yao
Hai Feng Pan
Xiang Pei Li
Jian Hua Xu
Dong Qing Ye
Publication date
01-09-2009
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 11/2009
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-0855-1

Other articles of this Issue 11/2009

Rheumatology International 11/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.